The cisatracurium besylate market was valued at USD458.4 Mn by 2019. Rising prevalence of pulmonary disorders and an increasing number of abdominal surgeries performed together to drive the cisatracurium besylate market growth. Furthermore the effective implementation of guidelines pertaining to anesthesia medicines the frequency of cisatracurium besylate as an anesthesia adjuvant has increased to a larger extent.

Cisatracurium besylate is a non-depolarizing skeletal muscle relaxant that is administered intravenously. It has an intermediate onset of action and duration of action likewise, it binds competitively with the cholinergic receptors on the motor plate end which eventually results in antagonizing the action of acetylcholine resulting in the blockade of neuromuscular transmission. It is an isomer of atracurium besylate with 3 folds potency in comparison to atracurium besylate. It degrades at physiological pH and temperature by organ independent Hoffman elimination by forming the compound called laudanosine which gets further metabolized and finally excreted via urine.

The major segments related to the cisatracurium besylate market are:

By Application (2017–2027; US$ Mn)

Mechanical Ventilation

Skeletal Muscle Relaxant

Others

By End User (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment(2017–2027; US$ Mn)

North America

United States
Canada

Europe

United Kingdom
Germany
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

• The intention of the study is to give a comprehensive outlook of the global cisatracurium besylate market
• The overall segmentation of the cisatracurium besylate market, by application, end-user and geography is minutely studied. Skeletal muscle relaxant and hospital pharmacy are dominating the application and end-user segments respectively
• Significant rise in the admission of critically ill patients in the intensive care units (ICU) and an increasing number of surgical procedures together drive the cisatracurium besylate market growth
• Effective implementation of guidelines pertaining to anesthesia has resulted in using cisatracurium besylate as an adjunct in general anesthesia 

Report gist?

• The study of the global cisatracurium besylate market includes qualitative analysis of factors such as drivers, restraints, and opportunities
• The report covers qualitative and quantitative analysis of the overall market segmented on the basis of application and end-user and categorization of the same at geography level
• This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027
• The study includes the profiles of major market players with a significant global and regional presence along with top company positioning 

Significant customers?

• This study is suitable for industry participants and stakeholders in the pharmaceutical companies engaged in manufacturing and marketing of cisatracurium besylate which is gaining huge demand on account of an increasing number of patients tracheal intubation in the intensive care units of hospitals worldwide
• The report will benefit anesthesiologist engaged in performing surgical procedures
• Managers with financial institutions looking to publish recent and forecasted statistics pertaining to cisatracurium besylate market
• Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Skeletal muscle relaxants are dominating the application segment for the cisatracurium besylate market. They are frequently employed for relaxing the muscles in the abdomen or chest region for surgeries to be performed in those regions. They are also employed for relaxing eye muscles in eye surgeries and permits easy movements of joints and bones during the joint surgery. Mechanical ventilation is anticipated to register faster growth in the near future on account of the rising prevalence of pulmonary disorders with breathing problems.

Hospital pharmacy is reigning the end-user segment for the cisatracurium besylate market. The positive attributes which determine its impressive market growth are immaculate drug dosage monitoring and precise compounding of skeletal muscle relaxant employed in surgical procedures in the intensive care units in the hospitals. Retail pharmacy is constantly growing in the developing nations on account of the presence of a huge generic drug market and the capability to provide medicines at affordable prices.

North America is holding the largest market share in the geography segment for the cisatracurium besylate market. The factors that determine its market dominance are a significant rise in the number of patients admitted in the intensive care units (ICU) receiving tracheal intubation in the treatment of pulmonary disorders. Furthermore the effective implementation of guidelines pertaining to anesthesia has included the popularity of using cisatracurium besylate as an anesthesia adjunct to facilitate mechanical ventilation. Domicile of major players such as AbbVie, Inc., GlaxoSmithKline, Plc., Sandoz, Inc., etc., further accelerates the market growth in the region. In Europe the market growth is driven by contributing factors such as affordable reimbursement scenario for the use of cisatracurium besylate in surgical procedures and proactive role adopted by the European Medical Agency (EMA) for the adoption of cisatracurium besylate as a skeletal muscle relaxant. Asia Pacific is set to register sturdy market growth owing to the rising prevalence of acute respiratory distress syndrome and trauma requiring mechanical ventilation to facilitate breathing and constant rise in the medical tourism industry.